BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3117 related articles for article (PubMed ID: 26907206)

  • 1. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
    Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
    Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
    Dongiovanni P; Romeo S; Valenti L
    World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
    Chen Y; Wang W; Morgan MP; Robson T; Annett S
    Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
    Hymel E; Vlock E; Fisher KW; Farazi PA
    PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 156.